Biogen Axes Schizophrenia Program, Touts Potential of Next Alzheimer's Drug

Medications
1

Schizophrenia Program Discontinued

A company with expertise in the difficult neurological and neuropsychology space, Biogen has had other struggles as well. After the failed Phase II TALLY study of BIIB104 in cognitive impairment linked to schizophrenia, Biogen has decided to discontinue the program for that indication.

2 Likes
2

We need more Alzheimer’s drugs.
Good for Biogen

2 Likes